Radical metastasectomy followed by sorafenib versus observation in patients withclear cell renal cell carcinoma: extended follow -up of efficacy results from the randomized phase II RESORT trial

A. Mennitto, E. Verzoni, F. Cognetti, R. Miceli, M. Milella, A. Mosca, V. E. Chiuri, A. Bearz, F. Morelli, C. Ortega, F. Atzori, M. Donini, M. Claps, V. Guadalupi, P. Sepe, V. Cappelletti, F. G. de Braud, G. Procopio

Research output: Contribution to journalArticlepeer-review

Abstract

Background: The RESORT trial showed no longer relapse free survival (RFS) with sorafenib following radical metastasectomy in metastatic renal cell carcinoma. We present the updated 42-month follow-up data. Methods: The phase II RESORT trial randomized patients to sorafenib or observation within 12 weeks from surgery. RFS was the primary endpoint. Results: We analyzed 68 patients (32 in sorafenib and 36 in the observation arm), randomized between November 2012 and November 2017. Eighty-one percent in the sorafenib arm and 80% in the observation arm had one metastasis. At a median follow-up of 42 months (interquartile range 31–58), in the observation arm the median RFS was 35 months, RFS probability was 57% (95% CI 42–76%) at 24 and 44% (95% CI 30–65%) at 48 months. In the sorafenib arm, median RFS was 21 months, RFS probability was 50% (95% CI 34–71%) at 24 and 32% (95% CI 18–57%) at 48 months (p = 0.342;HR 1.35;95% CI 0.72–2.54). Forty-seven percent and 37.5% of the patients in the two arms, respectively, are disease free. The site of relapses was independent of the previous metastasectomy site. Expert commentary: Sorafenib after metastasectomy did not improve RFS, but surgery in selected patients should be considered in order to potentially improve survival. Clinical trial registration: www.clinicaltrials.gov identifier is NCT0144480.

Original languageEnglish
JournalExpert Review of Clinical Pharmacology
DOIs
Publication statusAccepted/In press - 2021

Keywords

  • adjuvant treatment
  • Metastatic renal cell carcinoma
  • relapse-free survival
  • sorafenib
  • surgical metastasectomy
  • targeted therapy

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Radical metastasectomy followed by sorafenib versus observation in patients withclear cell renal cell carcinoma: extended follow -up of efficacy results from the randomized phase II RESORT trial'. Together they form a unique fingerprint.

Cite this